<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211017052785N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-06-14</date_registration>
      <primary_sponsor>Karaj University of Medical Sciences</primary_sponsor>
      <public_title>The effect of herbal medicine (Tiryaqe wabai) on anxiety, depression and sleep in the elderly</public_title>
      <acronym></acronym>
      <scientific_title>The effect of herbal medicine (Tiryaqe wabai) on anxiety, depression and sleep in the elderly: A double-blind randomized controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-08-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>108</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63809</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Assignment of individuals to the intervention and control groups will be done using block randomization method with the size of 4, 6 and 8 non-identical blocks (to hide the allocation). Statistical or web-based software such as https://www.sealedenvelope.com/simple-randomiser/v1/lists will be used for this purpose. In this method, the order of block size as well as the allocation of people in groups is randomly selected. In such a way that first 4, 6 or 8 blocks are randomly selected and in the selected block, the order of assigning individuals to the intervention and control group is determined randomly. In the study, they will be assigned to the intervention and control groups based on the production chain, respectively, Blinding description: For blinding, medicine and placebo are prepared, packaged and numbered by the pharmacist and the project manager and sampler will not be informed of their contents. Patients are also unaware that the capsule is taking medication or placebo.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Depression. Condition 2: anxiety disorder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: One capsule of Tiryaqe wabai is taken daily for 30 days one hour before dinner. Raw materials of medicine, prepared from reliable sources. And an initial assessment is made of its quality. Tiryaqe wabai is prepared by mixing Saffron powders, Aloe vera gel and Myhrr and according to the instructions mentioned in the sources of traditional medicine, including the Tohfat al mo'menin, the Exire A'zam,  and Tebe Akbari, and is packaged in the form of capsules. Standardization of the drug is done by measuring total phenol, determining the amount of crocin and alloine, as well as microbial control. Intervention 2: Control group: Take one placebo capsule daily for 30 days one hour before dinner. A suitable placebo is prepared with sufficient similarity and is prepared in similar packages of the drug.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data, such as information about the main consequences, can be shared by inserting it in the study article.

When:
Access period starts 8 months after the results are published

To whom:
Only for researchers working in academic and scientific institutions

Conditions:
Using data to advance scientific goals

Where to obtain:
Dr. Maarefvand

How to obtain:
Send the request for information via the announced gmail and the party will receive a response within a maximum of two weeks. dr.m.maarefvand@gmail.com

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mina Maarefvand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>45 meters from Golshahr - Saffarian Alley - Deputy of Research and Technology</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3198764653</zip>
        <telephone>+98 26 3464 3774</telephone>
        <email>dr.m.maarefvand@gmail.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mina Maarefvand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>45 meters from Golshahr - Saffarian Alley - Deputy of Research and Technology</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3198764653</zip>
        <telephone>+98 26 3464 3774</telephone>
        <email>dr.m.maarefvand@gmail.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Men and women aged 60 to 75 years referred to the health center of Karaj city
Having the desire and satisfaction to participate in the project
Obtain more than a quarter of the score from each of the three Depression, Sleep, and Anxiety Questionnaires</inclusion_criteria>
      <agemin>60 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Inability to take the drug in capsule form
Do not have a history of allergies to any of the ingredients used in the medicine
Do not change the amount of medication taken for any of the three conditions of anxiety, depression and sleep
Have serious underlying conditions such as uncontrolled blood pressure or diabetes, untreated ischemic heart disease, kidney and liver failure.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F34</hc_code>
      <hc_code>F41.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Persistent mood [affective] disorders</hc_keyword>
      <hc_keyword>Generalized anxiety disorder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: One capsule of Tiryaqe wabai is taken daily for 30 days one hour before dinner. Raw materials of medicine, prepared from reliable sources. And an initial assessment is made of its quality. Tiryaqe wabai is prepared by mixing Saffron powders, Aloe vera gel and Myhrr and according to the instructions mentioned in the sources of traditional medicine, including the Tohfat al mo'menin, the Exire A'zam,  and Tebe Akbari, and is packaged in the form of capsules. Standardization of the drug is done by measuring total phenol, determining the amount of crocin and alloine, as well as microbial control.</i_keyword>
      <i_keyword>Control group: Take one placebo capsule daily for 30 days one hour before dinner. A suitable placebo is prepared with sufficient similarity and is prepared in similar packages of the drug.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety Severity. Timepoint: Beginning and end of the study. Method of measurement: Hamilton Anxiety Questionnaire.</prim_outcome>
      <prim_outcome>Depression severity. Timepoint: Beginning and end of the study. Method of measurement: Beck Depression Inventory BDI-II.</prim_outcome>
      <prim_outcome>Sleep status. Timepoint: Beginning and end of the study. Method of measurement: Petersburg Sleep Quality Questionnaire (PSQI).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Karaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-21</approval_date>
        <contact_name>Ethics Committee of Alborz University of Medical Sciences</contact_name>
        <contact_address>45 meters from Golshahr - Saffarian Alley - Deputy of Research and Technology Alborz Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
